Mirati Therapeutics has patented a method for treating KRas G12C cancers by combining PD-1/PD-L1 inhibitors with specific KRAS G12C inhibitors. The patent covers the use of compounds like nivolumab and pembrolizumab in combination with certain formulas to treat cancer effectively. GlobalData’s report on Mirati Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Mirati Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Mirati Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents.

A recently granted patent (Publication Number: US11890285B2) discloses a method for treating KRas G12C-associated cancer by administering a combination of a PD-1/PD-L1 inhibitor and a specific compound. The method involves selecting from a group of PD-1/PD-L1 inhibitors such as nivolumab, pembrolizumab, cemiplimab, tislelizumab, atezolizumab, avelumab, and durvalumab, and combining it with a compound of a defined formula. The patent outlines various specific combinations and dosages for different PD-1 inhibitors, emphasizing the treatment of non-small cell lung cancer among other cancer types.

Furthermore, the patent describes methods to address resistance to treatment with PD-1/PD-L1 inhibitors in KRas G12C-associated cancer. It includes administering the specified combination to subjects who have developed resistance to these inhibitors, aiming to achieve a durable complete response. The patent also covers scenarios where resistance to KRas G12C inhibitors has developed, offering a comprehensive approach to treating and managing different types of cancer. The patent's detailed claims provide a roadmap for healthcare professionals to effectively treat patients with KRas G12C-associated cancer, highlighting the importance of personalized treatment strategies in oncology.

To know more about GlobalData’s detailed insights on Mirati Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies